Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin/Rosuvastatin Combination vs Monotherapy in T2DM and Dyslipidemia
NCT02827903Phase 3Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Jan 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Metformin + rosuvastatin in type 2 diabetes mellitus (T2DM), dyslipidemia, sponsored by Jeil Pharmaceutical Co., Ltd.. Started Jan 2016; status: completed.
02
Drugs
Metformin + rosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT02827903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02827903.